Dysfunctional CD11c^-CD21^- extrafollicular memory B cells are enriched in the periphery and tumors of patients with cancer.

ABSTRACT: Many patients with recurrent and metastatic cancer fail to produce a durable response to immunotherapy, highlighting the need for additional therapeutic targets to improve the immune landscape in tumors. Recent studies have highlighted the importance of B cells in the antitumor response, with memory B cells (MBCs) being prognostic in a variety of solid tumors. MBCs are a heterogenous B cell subset and can be generated through both germinal center reactions and extrafollicular (EF) responses. EF-derived MBCs have been recently linked to poor prognosis and treatment resistance in solid tumors and thus may represent candidate biomarkers or immunotherapy targets. EF-derived MBCs, termed "double-negative" (DN) MBCs may be further classified on the basis of surface expression of CD11c and CD21 i

SUBMITTER: Ruffin AT 

PROVIDER: S-EPMC12183695 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature